BR112019004791A2 - tratamento de esclerose múltipla com chs-131 - Google Patents

tratamento de esclerose múltipla com chs-131

Info

Publication number
BR112019004791A2
BR112019004791A2 BR112019004791A BR112019004791A BR112019004791A2 BR 112019004791 A2 BR112019004791 A2 BR 112019004791A2 BR 112019004791 A BR112019004791 A BR 112019004791A BR 112019004791 A BR112019004791 A BR 112019004791A BR 112019004791 A2 BR112019004791 A2 BR 112019004791A2
Authority
BR
Brazil
Prior art keywords
chs
multiple sclerosis
sclerosis treatment
treatment
prodrug
Prior art date
Application number
BR112019004791A
Other languages
English (en)
Portuguese (pt)
Inventor
Finck Barbara
Tang Hong
Zivadinov Robert
Original Assignee
Intekrin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intekrin Therapeutics Inc filed Critical Intekrin Therapeutics Inc
Publication of BR112019004791A2 publication Critical patent/BR112019004791A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112019004791A 2016-09-13 2017-09-13 tratamento de esclerose múltipla com chs-131 BR112019004791A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662394046P 2016-09-13 2016-09-13
US201662436356P 2016-12-19 2016-12-19
US201762460868P 2017-02-19 2017-02-19
US201762491071P 2017-04-27 2017-04-27
PCT/US2017/051414 WO2018053040A1 (en) 2016-09-13 2017-09-13 Treatment of multiple sclerosis with chs-131

Publications (1)

Publication Number Publication Date
BR112019004791A2 true BR112019004791A2 (pt) 2019-06-04

Family

ID=61619253

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019004791A BR112019004791A2 (pt) 2016-09-13 2017-09-13 tratamento de esclerose múltipla com chs-131

Country Status (12)

Country Link
US (1) US20190224186A1 (cg-RX-API-DMAC7.html)
EP (1) EP3512512A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019531286A (cg-RX-API-DMAC7.html)
KR (1) KR20190064583A (cg-RX-API-DMAC7.html)
CN (1) CN110461318A (cg-RX-API-DMAC7.html)
AU (1) AU2017326261A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019004791A2 (cg-RX-API-DMAC7.html)
CA (1) CA3036694A1 (cg-RX-API-DMAC7.html)
IL (1) IL265259A (cg-RX-API-DMAC7.html)
MX (1) MX2019002901A (cg-RX-API-DMAC7.html)
SG (1) SG10202102198RA (cg-RX-API-DMAC7.html)
WO (1) WO2018053040A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
EA201992364A1 (ru) * 2018-04-02 2020-03-23 Кохерус Байосайенсис Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
MX2015004564A (es) * 2012-10-12 2015-07-21 Teva Pharma Laquinimod para producir el daño talamico en la esclerosis multiple.
HK1218510A1 (zh) * 2013-01-30 2017-02-24 Intekrin Therapeutics, Inc. 用於治療多發性硬化症的PPARγ激動劑

Also Published As

Publication number Publication date
CN110461318A (zh) 2019-11-15
IL265259A (en) 2019-05-30
JP2019531286A (ja) 2019-10-31
EP3512512A1 (en) 2019-07-24
CA3036694A1 (en) 2018-03-22
KR20190064583A (ko) 2019-06-10
EP3512512A4 (en) 2020-06-03
AU2017326261A1 (en) 2019-04-04
US20190224186A1 (en) 2019-07-25
WO2018053040A1 (en) 2018-03-22
MX2019002901A (es) 2019-09-26
SG10202102198RA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2024004439A (es) Agentes terapeuticos para enfermedades neurodegenerativas
MX2024010140A (es) Nuevos metodos.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX387115B (es) Métodos para tratar la influenza.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX384403B (es) Terapia de combinación para el tratamiento del cáncer.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
BR112017003571A2 (pt) terapia combinada
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX382754B (es) Terapias combinadas para tratar el cancer.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.